PE79699A1 - Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos - Google Patents

Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos

Info

Publication number
PE79699A1
PE79699A1 PE1998000471A PE00047198A PE79699A1 PE 79699 A1 PE79699 A1 PE 79699A1 PE 1998000471 A PE1998000471 A PE 1998000471A PE 00047198 A PE00047198 A PE 00047198A PE 79699 A1 PE79699 A1 PE 79699A1
Authority
PE
Peru
Prior art keywords
alkyl
members
ring
ch2nr8r15
polyclic
Prior art date
Application number
PE1998000471A
Other languages
English (en)
Inventor
Brian Scott Bronk
Takushi Kaneko
Edward Alan Glazer
Hengmiao Cheng
Bingwei Vera Yang
Michael Anthony Letavic
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21959336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE79699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE79699A1 publication Critical patent/PE79699A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (1), O SU SAL, DONDE R1 ES H, OH o METOXI; R2 ES OH; R3 ES ALQUILO C1-C10, -CH2S(O)nR8, -CH2N(OR9)R8, -CH2NR8R15, -(CH2)m-(ARILO C6-C10), n ES 0-2, m ES 0-4; o R2 Y R3 FORMAN UN ANILLO OXAZOLILO DE FORMULA (a); R4 ES H, -C(O)R9, -C(O)OR9, C(O)NR9R10 O UN GRUPO PROTECTOR DE HIDROXI; R5 ES -SR8, -(CH2)nC(O)R8, ALQUILO C1-C10, ENTRE OTROS; R6 Y R7 SON H, OH, ALCOXI C1-C6, ENTRE OTROS; R8 ES H, ALQUILO C1-C10, -(CH2)qCR11R12(CH2)r-NR13R14, ENTRE OTROS, q o r SON 0-3, PERO NO SON AMBOS CERO; CUANDO R8 ES -CH2NR8R15, R15 Y R8 FORMAN UN ANILLO MONO O POLICICLICO SATURADO DE 4-10 MIEMBROS; R3, R5, R8 OPCIONALMENTE SUSTITUIDOS CON 1-3 GRUPOS R16; R9 Y R10 SON H O ALQUILO C1-C6; R11, R12, R13 Y R14 SON H, ALQUILO C1-C10, -(CH2)m(ARILO C6-C10), ENTRE OTROS o R11 Y R13 FORMAN JUNTOS -(CH2)p-, p ES 0-3, FORMANDO UN ANILLO SATURADO DE 4-7 MIEMBROS CON 1-2 DOBLES O TRIPLES ENLACES o R13 Y R14 FORMAN UN ANILLO MONO O POLICICLICO DE 4-10 MIEMBROS O HETEROARILO DE 5-10 MIEMBROS CON 1-2 O, S Y -N(R8)-; R15 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10; R16 ES HALOGENO, CIANO, NITRO, ENTRE OTROS; R17 ES H, ALQUILO C1-C10, ALQUENILO C2-C10. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION BACTERIANA O PROTOZOARIA
PE1998000471A 1997-06-11 1998-06-08 Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos PE79699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4934897P 1997-06-11 1997-06-11

Publications (1)

Publication Number Publication Date
PE79699A1 true PE79699A1 (es) 1999-08-25

Family

ID=21959336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000471A PE79699A1 (es) 1997-06-11 1998-06-08 Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos

Country Status (50)

Country Link
US (4) US6420536B1 (es)
EP (1) EP0988310B9 (es)
JP (2) JP3315704B2 (es)
KR (1) KR100396168B1 (es)
CN (4) CN1172947C (es)
AP (1) AP1231A (es)
AR (1) AR013086A1 (es)
AT (1) ATE251173T1 (es)
AU (1) AU749816B2 (es)
BG (1) BG64391B1 (es)
BR (1) BRPI9810519B8 (es)
CA (1) CA2293823C (es)
CO (1) CO4950611A1 (es)
CZ (1) CZ298556B6 (es)
DE (2) DE122004000018I2 (es)
DK (1) DK0988310T3 (es)
DZ (1) DZ2514A1 (es)
EA (1) EA002441B1 (es)
EG (1) EG24081A (es)
ES (1) ES2205487T3 (es)
FR (1) FR04C0013I2 (es)
GT (1) GT199800077A (es)
HK (3) HK1028048A1 (es)
HN (1) HN1998000086A (es)
HR (1) HRP980314B1 (es)
HU (2) HU228005B1 (es)
ID (1) ID22992A (es)
IL (1) IL132809A0 (es)
IS (1) IS1998B (es)
LU (1) LU91076I9 (es)
MA (1) MA24564A1 (es)
ME (1) ME00876B (es)
MY (1) MY123354A (es)
NL (1) NL300150I2 (es)
NO (1) NO316911B1 (es)
NZ (2) NZ514871A (es)
OA (1) OA11224A (es)
PA (1) PA8452201A1 (es)
PE (1) PE79699A1 (es)
PL (1) PL191601B1 (es)
PT (1) PT988310E (es)
RS (1) RS49675B (es)
SI (1) SI0988310T1 (es)
SK (1) SK284171B6 (es)
TN (1) TNSN98082A1 (es)
TW (1) TW472060B (es)
UA (1) UA67744C2 (es)
UY (1) UY25040A1 (es)
WO (1) WO1998056802A1 (es)
ZA (1) ZA985017B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
EP1011689B8 (en) * 1997-09-10 2007-05-09 Merial Ltd. USE OF 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
EP1779853A3 (en) * 1997-09-10 2010-01-27 Merial Ltd. 9a-azalides as veterinary antimicrobial agents
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
US6100240A (en) * 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
CA2292359C (en) * 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
PL353316A1 (en) * 1999-05-18 2003-11-17 Pfizer Products Inc. Novel crystalline forms of a macrolide antibiotic
IL145739A0 (en) * 1999-05-24 2002-07-25 Pfizer Prod Inc 13-methyl-erythromycin derivatives
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
EP1206476B1 (en) * 1999-08-24 2006-01-04 Abbott Laboratories 9a-azalides with antibacterial activity
US6608033B1 (en) * 1999-08-27 2003-08-19 Pfizer Inc. Treatment or prevention of coccidiosis
NZ518665A (en) * 2000-01-27 2005-02-25 Pfizer Prod Inc Azalide antibiotic compositions
WO2001081358A1 (en) * 2000-04-27 2001-11-01 Pfizer Products Inc. The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
BR0209241A (pt) * 2001-04-27 2004-06-15 Pfizer Prod Inc Processo para preparação de derivados de9-deoxo-9a-aza-9a-homoeritromicina a 4-substituida
WO2003011266A2 (en) * 2001-08-01 2003-02-13 Pfizer Products Inc. Azalide antibiotic compositions
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
CN1882360A (zh) * 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
EP2295422A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
DE602006006546D1 (de) * 2005-01-14 2009-06-10 Glaxosmithkline Zagreb 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
SI2358379T1 (sl) 2008-10-24 2016-05-31 Cempra Pharmaceuticals, Inc. Postopki biološke obrambe z makrolidi, ki vsebujejo triazol
US9937194B1 (en) * 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
KR20180101643A (ko) 2010-03-22 2018-09-12 셈프라 파마슈티컬스, 인크. 매크로라이드의 결정 형태들 및 그 용도들
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
KR20180110181A (ko) 2010-09-10 2018-10-08 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
EP2619214B1 (en) 2010-09-20 2014-12-24 Novartis AG Novel process for the preparation of 9-deoxo-9a-aza-9a-homoerythromycin a modified in the c-4'' of the cladinose ring by an epoxide group
US9145436B2 (en) * 2010-10-10 2015-09-29 Michael W. Burnet Anti-inflammatory macrolides
CN102993250B (zh) * 2011-07-06 2016-02-10 洛阳惠中兽药有限公司 C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物
CN102260306B (zh) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 一种制备泰拉霉素的方法
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
CN102786569B (zh) * 2012-09-07 2016-12-07 安徽中升药业有限公司 泰拉霉素中间体及其制备方法与泰拉霉素的制备方法
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
WO2015014907A1 (en) * 2013-07-31 2015-02-05 Farma Grs, D.O.O. Process for preparation of tulathromycin
CN103497227B (zh) * 2013-09-13 2015-09-30 青岛科技大学 一种泰拉菌素中间体的制备方法
CN104725446B (zh) * 2015-03-26 2017-10-27 宁夏泰瑞制药股份有限公司 一种从泰拉霉素粗品中分离泰拉霉素a和泰拉霉素b的方法
CN104861018A (zh) * 2015-06-17 2015-08-26 瑞普（天津）生物药业有限公司 一种泰拉菌素的制备方法
CN105646617A (zh) * 2016-01-21 2016-06-08 杭州海尔希畜牧科技有限公司 一种制备泰拉霉素的方法
FR3048612B1 (fr) * 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
CN106046077B (zh) * 2016-08-04 2019-07-26 湖北美天生物科技股份有限公司 一种泰拉霉素a的合成方法
CN108003207B (zh) 2017-12-19 2019-05-10 海门慧聚药业有限公司 制备泰拉霉素的方法
CN111087433B (zh) * 2018-10-23 2023-03-21 湖北美天生物科技股份有限公司 一种泰拉霉素中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
US5226958A (en) * 1991-04-11 1993-07-13 Pacemark, Inc. Sealant for pneumatic inner tubes and tubeless tires
EP0549040A1 (en) * 1991-12-20 1993-06-30 Merck & Co. Inc. Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
UA70972C2 (uk) 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
AR013086A1 (es) 2000-12-13
DE69818665T2 (de) 2004-04-29
CN1566129A (zh) 2005-01-19
EP0988310B9 (en) 2006-03-08
ME00876B (me) 2012-06-20
NO316911B1 (no) 2004-06-21
SK284171B6 (sk) 2004-10-05
PA8452201A1 (es) 2000-05-24
FR04C0013I2 (es) 2005-10-21
HN1998000086A (es) 1999-03-08
NZ500660A (en) 2002-03-01
DZ2514A1 (fr) 2003-02-01
DE122004000018I1 (de) 2004-09-30
US6777393B2 (en) 2004-08-17
BRPI9810519A (pt) 2000-09-19
SI0988310T1 (en) 2004-02-29
PL191601B1 (pl) 2006-06-30
AU7347598A (en) 1998-12-30
IS5252A (is) 1999-11-16
JP3315704B2 (ja) 2002-08-19
CA2293823A1 (en) 1998-12-17
JP2002316933A (ja) 2002-10-31
PT988310E (pt) 2003-12-31
CN1243766C (zh) 2006-03-01
LU91076I2 (fr) 2004-07-05
KR100396168B1 (ko) 2003-08-27
ATE251173T1 (de) 2003-10-15
AP1231A (en) 2003-12-11
HRP980314A2 (en) 1999-04-30
CZ442199A3 (cs) 2000-07-12
TW472060B (en) 2002-01-11
CN101691390A (zh) 2010-04-07
DK0988310T3 (da) 2003-12-15
DE69818665D1 (de) 2003-11-06
AP9801255A0 (en) 1998-06-30
KR20010013632A (ko) 2001-02-26
IL132809A0 (en) 2001-03-19
HUP0002209A3 (en) 2003-05-28
MA24564A1 (fr) 1998-12-31
US20040023896A1 (en) 2004-02-05
NO996106D0 (no) 1999-12-10
JP2000514098A (ja) 2000-10-24
BRPI9810519B1 (pt) 2012-02-22
MY123354A (en) 2006-05-31
HK1028048A1 (en) 2001-02-02
BG103945A (en) 2000-07-31
CA2293823C (en) 2004-02-17
IS1998B (is) 2005-03-15
HUS1200028I1 (hu) 2016-08-29
EA002441B1 (ru) 2002-04-25
HK1088014A1 (en) 2006-10-27
DE122004000018I2 (de) 2011-01-13
US20040180842A1 (en) 2004-09-16
HRP980314B1 (en) 2004-04-30
ES2205487T3 (es) 2004-05-01
TNSN98082A1 (fr) 2005-03-15
GT199800077A (es) 1999-12-02
OA11224A (en) 2003-07-16
BRPI9810519B8 (pt) 2022-11-16
HU228005B1 (en) 2012-08-28
NZ514871A (en) 2003-08-29
EP0988310A1 (en) 2000-03-29
HUP0002209A2 (hu) 2000-12-28
CN1259136A (zh) 2000-07-05
NL300150I1 (nl) 2004-08-02
CZ298556B6 (cs) 2007-11-07
FR04C0013I1 (es) 2004-06-11
CN1793155B (zh) 2010-05-12
SK168399A3 (en) 2000-11-07
US6936592B2 (en) 2005-08-30
AU749816B2 (en) 2002-07-04
UY25040A1 (es) 2000-09-29
CO4950611A1 (es) 2000-09-01
ZA985017B (en) 1999-12-17
RS49675B (sr) 2007-11-15
YU58699A (es) 2002-08-12
BG64391B1 (bg) 2004-12-30
NL300150I2 (nl) 2004-09-01
WO1998056802A1 (en) 1998-12-17
LU91076I9 (en) 2018-07-02
NO996106L (no) 2000-02-10
HK1068893A1 (en) 2005-07-29
UA67744C2 (uk) 2004-07-15
US6420536B1 (en) 2002-07-16
US20020061858A1 (en) 2002-05-23
PL337505A1 (en) 2000-08-28
ID22992A (id) 1999-12-23
EG24081A (en) 2008-05-11
CN1172947C (zh) 2004-10-27
EP0988310B1 (en) 2003-10-01
CN1793155A (zh) 2006-06-28
EA199901015A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
PE79699A1 (es) Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos
PE79999A1 (es) Derivados de macrolidos c-4" sustituidos
PE23196A1 (es) Compuesto util para tratar infecciones por retrovirus
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
PE49696A1 (es) Compuesto carbociclico
ES2155566T3 (es) Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.
JPS5598179A (en) Novel arylether*its manufacture and drug containing same for treating allergic disease
PE99098A1 (es) Derivados de 14-o-carbamoilo de mutilina
FR2387988A1 (fr) Esters de cefuroxime, leur preparation et leur application therapeutique
FR2370028A1 (fr) Hydroxylamines alkylees, leur procede de preparation et leur emploi comme medicaments
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
EP0269899A3 (en) Use of aromatic carboxylic-acid amides
FR2617476B1 (fr) Nouveaux derives polycycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
DE69018730D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
FR2400008A1 (fr) Agents anti-hypertensifs
ES2116601T3 (es) Derivados de isoquinolina como agentes terapeuticos.
DE3750464T2 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
ES528816A0 (es) Procedimiento de producir compuestos para el tratamiento de la hipertension
KR910018341A (ko) 신규 α-만노시다제 및 푸코시다제 억제제
ES550742A0 (es) Un procedimiento para la preparacion de una octahidroindo- lizina
ES2041679T3 (es) Compuestos analgesicos de octohidroindolizinas 5-substituidas y productos intermedios 7-ceto.
ZA91886B (en) Indole derivatives,their preparation and use
FR2355846A1 (fr) Esters de penicillines utilisables comme medicaments
FR2355501A1 (fr) Nouvelles 2-(ethyl 2,2-disubstitue)-imidazolines, utiles notamment pour le traitement du diabete
FR2389624A1 (es)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed